Many drugs used to treat non-cardiac conditions are known to have off-target cardiovascular effects including arrhythmias, hypertension, and reduced ventricular function, which may lead to increased cardiac risk and possibly death. This presents a major challenge not only for clinicians who administer these medications, but also for sponsors who have invested significant time, resources, and money to develop effective therapeutic treatments. As such, cardiac safety monitoring has drawn considerable attention from the pharmaceutical and biotech industries, clinicians…
Mark Weinstein, President and CEO, BioClinica. BioClinica Inc. is a global provider of integrated, technology-enhanced clinical trial management services. BioClinica offers clinical trial management technology and expertise resulting from more than 28 years of experience. For more information, visit bioclinica.com.